Is a GLP-1 worth the money?

That is not a question a comparison site can answer for someone, but it can supply the arithmetic: $299 a month at the cheapest verified route to an FDA-approved GLP-1 for weight (Foundayo) is roughly $3,588 across a year, counting the twelve 30-day bottles a year holds. Whether the trial figures justify that depends on the indication, the coverage and the person.

What is the strongest argument against starting one?

Cost combined with open-endedness. Not the side effects — those are documented, mostly gastrointestinal and mostly worst after a dose step. The harder problem is that the price recurs indefinitely and the cash route builds nothing toward a plan's out-of-pocket cap.

Are the cheaper compounded versions the same thing?

The same molecule where the pharmacy uses semaglutide base, and not the same product: no FDA review of that formulation, no inspection to the approved standard, and a legal status under active litigation.

← GLP-1s explained, from the top

The case for and against a GLP-1

The honest version of this list is shorter than most and has numbers in it. What follows is drawn from the labels, the named trials and the prices verified on this site — not from a balance of opinions.

No clinician has reviewed this page. Label and trial statements are quoted from the FDA label or the trial cited beside them. General guidance is marked as such, and every price carries the date it was verified. That is sourcing, not medical review. What we do and do not check · Who checked the price

Last updated 2026-09-22 — the prices and figures quoted below. Read and dated by Alex Seot.

What are the pros and cons of GLP-1 drugs?

The trial figures are the strongest thing in their favor and they are large: Zepbound 20.9%, Wegovy 14.9%, Wegovy pill 13.6% mean weight loss, each in the trial its own label cites.

Those trials also measured things people do not search for and that matter more than the scale: Wegovy's label carries a cardiovascular indication, and Zepbound carries one for moderate to severe obstructive sleep apnea. Where one of those applies, the drug is coverable under a plan that refuses it for weight alone — which changes the price question completely.

Verified all-in prices for a GLP-1 on this site run $129 to $548 a month, and a year is not twelve times a month: the early months are a different dose at a different price, and a box of weekly pens lasts 28 days, which makes a year of injections thirteen fills.

The cash price also buys nothing toward a deductible or an out-of-pocket maximum, because it sits outside the plan entirely. And the conditional self-pay rates are conditional: miss a refill window and the higher doses re-price.

What the labels warn about

Every GLP-1 in this class carries a boxed warning for thyroid C-cell tumors, seen in rodents, with the human relevance not determined — which is what the label says rather than a reassurance or an alarm. Contraindications include a personal or family history of medullary thyroid carcinoma and MEN 2.

The common reactions are gastrointestinal and cluster just after a dose increase rather than at a steady dose: nausea, diarrhea, vomiting, constipation. Pancreatitis and gallbladder disease appear in the serious lists. The per-drug pages quote each label in full rather than summarizing across them.

The two cons nobody writes on the pro side

It is not a course with an end. The pricing is built around continuing refills, and what happens on stopping is the question the trials that measured regain were designed to answer. Planning around a year of it and then stopping is a different decision from planning around it indefinitely.

And the cheap route is cheap for a reason. Compounded versions cost a fraction and are not FDA approved or reviewed; the exemption they are made under is being litigated, and a pharmacy that is enjoined stops shipping to the people relying on it.

Every price, ranked →What a year actually costs →What a pharmacy pays →FDA warning letters →What a GLP-1 is, and what each one costs →GLP-1 vs GLP-3 →Is compounded semaglutide safe? →

Questions

Is a GLP-1 worth the money?: That is not a question a comparison site can answer for someone, but it can supply the arithmetic: $299 a month at the cheapest verified route to an FDA-approved GLP-1 for weight (Foundayo) is roughly $3,588 across a year, counting the twelve 30-day bottles a year holds. Whether the trial figures justify that depends on the indication, the coverage and the person.
What is the strongest argument against starting one?: Cost combined with open-endedness. Not the side effects — those are documented, mostly gastrointestinal and mostly worst after a dose step. The harder problem is that the price recurs indefinitely and the cash route builds nothing toward a plan's out-of-pocket cap.
Are the cheaper compounded versions the same thing?: The same molecule where the pharmacy uses semaglutide base, and not the same product: no FDA review of that formulation, no inspection to the approved standard, and a legal status under active litigation.

What this rests on

FDA prescribing information for WEGOVY (semaglutide)The cardiovascular indication, the boxed warning for thyroid C-cell tumors, the contraindications for medullary thyroid carcinoma and MEN 2, and the gastrointestinal reactions.
FDA prescribing information for ZEPBOUND (tirzepatide)The indication for moderate to severe obstructive sleep apnea, which is the approval a weight-loss exclusion does not reach.
FDA prescribing information for MOUNJARO (tirzepatide)That the same molecule is sold under two labels at prices that differ.
FDA prescribing information for SAXENDA (liraglutide)That the boxed warning and the contraindications are shared across the class rather than specific to one drug.
FDA: concerns with unapproved GLP-1 drugs used for weight lossWhy the cheap route is cheap, and what the agency says is not known about it.

Every figure above is read from the page of the drug or seller it names, which records where it came from and the date it was verified. Every clinical statement is quoted from one of the labels listed above, never interpreted. Information only, not medical advice.